William Grossman Acquires 231,000 Shares of enGene Therapeutics
The Interim Chief Medical Officer made a significant purchase on June 16, 2026.
Key Points
- William Grossman, Interim Chief Medical Officer at enGene Therapeutics, bought 231,000 shares on June 16, 2026.
- enGene Therapeutics, trading at $1.75, has a market cap of about $117.2 million and a 52-week range of $1.40 to $12.25.
- The company focuses on genetic medicines for bladder cancer and operates as a clinical-stage biotech firm in Montreal.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
William Grossman, the Interim Chief Medical Officer of enGene Therapeutics Inc. (NasdaqCM:ENGN), recently acquired 231,000 shares of the company. This insider transaction took place on June 16, 2026, and reflects Grossman's continued involvement with the company, though the purchase price was not disclosed.
enGene Therapeutics Inc. Stock Down 4.7%
Shares of enGene Therapeutics traded around $1.75 recently. The company has a market capitalization of approximately $117.2 million. enGene is not currently profitable, as indicated by its forward P/E ratio of -1.04. The stock has experienced a wide 52-week price range, with a low of $1.40 and a high of $12.25. Its 50-day moving average stands at $4.33, while the 200-day moving average is $7.13. Financially, the company maintains a current ratio of 12.57 and a quick ratio of 12.07, with a debt-to-equity ratio of 13.07.
About enGene Therapeutics
enGene Therapeutics Inc. is a biotechnology company based in Montreal, Canada. It focuses on developing genetic medicines, particularly for patients suffering from bladder cancer. The company's leading product candidate is detalimogene voraplasmid, which is aimed at treating non-muscle invasive bladder cancer. enGene is also advancing a project known as LEGEND, currently in Phase 2 trials. The company, led by CEO Ronald H. W. Cooper, was formerly known as enGene Holdings Inc. before its name change in April 2026.
Bottom Line
William Grossman's significant share purchase underscores his commitment to enGene Therapeutics. As a clinical-stage biotech company, enGene is working on innovative treatments for bladder cancer, which could be promising for future growth. Investors often keep a close eye on insider transactions, as they can signal confidence in a company's prospects. However, it's important to remember that such transactions are just one piece of the broader investment puzzle.
Get enGene Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $ENGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.